IDXX
NASDAQIDEXX Laboratories Inc.
Price$561.00-8.29 (-1.46%)
01:30 PM07:45 PM
News · 26 weeks48-70%
2025-10-262026-04-19
Mix3490d
- Insider19(56%)
- SEC Filings9(26%)
- Other3(9%)
- Earnings2(6%)
- Analyst1(3%)
Latest news
25 items- ANALYSTCitigroup initiated coverage on IDEXX Labs with a new price targetCitigroup initiated coverage of IDEXX Labs with a rating of Neutral and set a new price target of $650.00
- PRIDEXX Laboratories to Release 2026 First Quarter Financial ResultsIDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 first quarter financial results for Tuesday, May 5, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q1 2026 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen to
- PRIDEXX Announces UK Availability of Cancer Dx Panel for Early Detection of Canine LymphomaHelping clinicians investigate sooner and plan next steps with confidence IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the availability of the IDEXX Cancer Dx™ Panel in the United Kingdom, beginning with early detection of lymphoma in at-risk* dogs. The blood test can be added to panels for sick pets and integrated into regular wellness screenings, with veterinarian pricing starting from £22.50† and results available to UK practices within 3–5 business days. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401831720/en/IDEXX Cancer Dx Panel with lymphoma testing Cancer
- SECSEC Form DEFA14A filed by IDEXX Laboratories Inc.DEFA14A - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
- SECSEC Form DEF 14A filed by IDEXX Laboratories Inc.DEF 14A - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by IDEXX Laboratories Inc.SCHEDULE 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)
- SECIDEXX Laboratories Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
- SECSEC Form PRE 14A filed by IDEXX Laboratories Inc.PRE 14A - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
- INSIDEREVP, GC & Corporate Secretary Underberg Sharon E. exercised 197 shares at a strike of $505.53, increasing direct ownership by 3% to 7,138 units (SEC Form 4)4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- INSIDERExecutive Vice President Hunt Nimrata sold $1,115,577 worth of shares (1,758 units at $634.57), decreasing direct ownership by 9% to 18,141 units (SEC Form 4)4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Executive Vice President Erickson Michael G4/A - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- SECSEC Form 144 filed by IDEXX Laboratories Inc.144 - IDEXX LABORATORIES INC /DE (0000874716) (Subject)
- INSIDERPresident and CEO Mazelsky Jonathan Jay exercised 23,523 shares at a strike of $144.65 and sold $15,338,081 worth of shares (23,326 units at $657.55), increasing direct ownership by 0.24% to 83,803 units (SEC Form 4)4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- INSIDERExecutive Vice President Hunt Nimrata sold $1,781,531 worth of shares (2,693 units at $661.54), decreasing direct ownership by 12% to 19,899 units (SEC Form 4)4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- SECSEC Form 10-K filed by IDEXX Laboratories Inc.10-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
- INSIDERExecutive Vice President Erickson Michael G exercised 7,770 shares at a strike of $187.94 and sold $3,369,666 worth of shares (5,371 units at $627.38), increasing direct ownership by 19% to 15,092 units (SEC Form 4)4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- INSIDERDirector Vandebroek Sophie V. exercised 945 shares at a strike of $333.90 and sold $920,293 worth of shares (1,464 units at $628.62), decreasing direct ownership by 44% to 648 units (SEC Form 4)4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- INSIDEREVP, GC & Corporate Secretary Underberg Sharon E. converted options into 832 shares and covered exercise/tax liability with 251 shares, increasing direct ownership by 9% to 6,941 units (SEC Form 4)4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- INSIDERExecutive Vice President Smith Martin Alexander converted options into 1,004 shares and covered exercise/tax liability with 302 shares, increasing direct ownership by 48% to 2,157 units (SEC Form 4)4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- INSIDERExecutive Vice President Schreck Michael converted options into 1,959 shares and covered exercise/tax liability with 876 shares, increasing direct ownership by 54% to 3,089 units (SEC Form 4)4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- INSIDERPresident and CEO Mazelsky Jonathan Jay converted options into 2,057 shares and covered exercise/tax liability with 915 shares, increasing direct ownership by 1% to 83,606 units (SEC Form 4)4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- INSIDERExecutive Vice President Lane Michael converted options into 1,092 shares and covered exercise/tax liability with 221 shares, increasing direct ownership by 12% to 8,024 units (SEC Form 4)4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- INSIDERExecutive Vice President Johnson Michael Perkins converted options into 573 shares and covered exercise/tax liability with 178 shares, increasing direct ownership by 16% to 2,795 units (SEC Form 4)4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- INSIDERExecutive Vice President Hunt Nimrata converted options into 2,587 shares and covered exercise/tax liability with 1,154 shares, increasing direct ownership by 7% to 22,592 units (SEC Form 4)4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- INSIDERExecutive Vice President Fennell George covered exercise/tax liability with 199 shares and converted options into 454 shares, increasing direct ownership by 3% to 10,078 units (SEC Form 4)4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)